Vivo Capital LLC Cuts Position in Viridian Therapeutics, Inc. $VRDN

Vivo Capital LLC trimmed its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 83.1% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 166,288 shares of the company's stock after selling 816,288 shares during the period. Vivo Capital LLC owned approximately 0.16% of Viridian Therapeutics worth $3,253,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Viridian Therapeutics in the 4th quarter valued at $36,000. KBC Group NV purchased a new position in Viridian Therapeutics during the 1st quarter valued at about $34,000. Larson Financial Group LLC purchased a new position in Viridian Therapeutics during the 3rd quarter valued at about $52,000. US Bancorp DE grew its position in Viridian Therapeutics by 23.2% in the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company's stock valued at $53,000 after acquiring an additional 463 shares in the last quarter. Finally, State of Wyoming acquired a new position in Viridian Therapeutics in the 1st quarter valued at about $93,000.

Insiders Place Their Bets

In other news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of the firm's stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $17.00 per share, for a total transaction of $19,999,990.00. Following the completion of the purchase, the director directly owned 5,090,928 shares of the company's stock, valued at $86,545,776. The trade was a 30.05% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.40% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the stock. Evercore set a $26.00 price target on shares of Viridian Therapeutics in a research report on Friday, May 15th. Wedbush lifted their price objective on shares of Viridian Therapeutics from $32.00 to $43.00 and gave the company an "outperform" rating in a report on Tuesday, June 30th. Weiss Ratings downgraded shares of Viridian Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 30th. Stifel Nicolaus set a $39.00 target price on shares of Viridian Therapeutics in a research note on Wednesday, May 13th. Finally, Truist Financial increased their target price on shares of Viridian Therapeutics from $35.00 to $38.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. Thirteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.79.

Viridian Therapeutics Price Performance

VRDN stock opened at $19.90 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 15.15 and a quick ratio of 15.15. The firm has a market capitalization of $2.05 billion, a P/E ratio of -5.99 and a beta of 0.90. The business's 50-day moving average is $17.93 and its two-hundred day moving average is $22.09. Viridian Therapeutics, Inc. has a 1 year low of $13.18 and a 1 year high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The business had revenue of $0.14 million during the quarter, compared to analysts' expectations of $0.04 million. During the same quarter last year, the business posted ($0.87) EPS. The business's quarterly revenue was up 95.8% compared to the same quarter last year. Analysts anticipate that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current fiscal year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.

Want to see what other hedge funds are holding VRDN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.